TPI Signs Macrolide API International Sales and Marketing Agreement

CHENGDU, China, June 15, 2011 /PRNewswire-Asia-FirstCall/ —
Tianyin Pharmaceutical Co., Inc. (NYSE Amex:
TPI), a pharmaceutical company that specializes in patented
biopharmaceutical medicine, modernized traditional Chinese
medicine, branded generics and active pharmaceutical ingredients
(API) today announced that the signing of the sales and marketing
agreement with RELATIONS International Ltd., a Bangladesh
corporation that specializes in the API sales for its Azithromycin
API product sales in the People’s Republic of Bangladesh.
“The signing of the agreement demonstrates our effort in
further developing our macrolide antibiotic API business
internationally,” said Dr. Jiang, Chairman and CEO of
TPI.

TPI forecasts $30 million domestic Azithromycin API revenue in
China for the first year of operation from its Jiangchuan macrolide
facility (JCM) that has an annual manufacturing capacity of 250
tons. The international sales revenue from macrolide API is
expected to contribute additional revenue for TPI.

Currently the JCM’s license for manufacturing Azithromycin API
is active (H10970072). Additional information regarding JCM can be
found at www.sfda.gov.cn (Chinese
version).

About TPIHeadquartered at Chengdu, China, TPI is a
pharmaceutical company that specializes in the development,
manufacturing, marketing and sales of patented biopharmaceutical,
modernized traditional Chinese medicines, branded generics and
active pharmaceutical ingredients (API). TPI currently manufactures
a comprehensive portfolio of 58 products, 24 of which are listed in
the highly selective national medicine reimbursement list, 7 are
included in the essential drug list of China. TPI’s pipeline
targets various high incidence healthcare indications. TPI has an
extensive nationwide distribution network with a sales force of 730
sales re

‘/>”/>

SOURCE